NFG
GNRX

Next Financial Group’s VanEck Vectors Generic Drugs ETF GNRX Stock Holding History

Next Financial Group’s Portfolio GNRX Stock Details GNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-300
Closed -$6K – 2522
2016
Q4 		$6K Hold
300
– – ﹤0.01% 1897
2016
Q3 		$7K Buy
+300
New +$7.5K ﹤0.01% 1838

Other funds holding GNRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Next Financial Group's GNRX Position: Q1 2017 in Review

Next Financial Group sold out of VanEck Vectors Generic Drugs ETF (GNRX) in Q1 2017, closing a stake of 300 shares — an estimated $6K sold.

Next Financial Group first reported a position in GNRX in Q3 2016 and held it in 2 quarters. The position peaked at $7K in Q3 2016. 4 funds tracked by Wall St. Rank hold GNRX as of Q1 2017.

  • Next Financial Group reported no remaining VanEck Vectors Generic Drugs ETF position as of Q1 2017 after selling out during the quarter.
  • Next Financial Group sold 300 VanEck Vectors Generic Drugs ETF shares in Q1 2017, an estimated $6K.
  • Next Financial Group first reported a position in VanEck Vectors Generic Drugs ETF in Q3 2016 and held it in 2 quarters.
  • Next Financial Group's VanEck Vectors Generic Drugs ETF position peaked at $7K in Q3 2016.
  • 4 funds tracked by Wall St. Rank held VanEck Vectors Generic Drugs ETF as of Q1 2017.

Based on Next Financial Group's 13F filing for Q1 2017, filed 8 May 2017.